122 related articles for article (PubMed ID: 18384543)
21. Treatment of palmoplantar psoriasis with intramuscular alefacept.
Myers W; Christiansen L; Gottlieb AB
J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 1):S127-9. PubMed ID: 16021161
[TBL] [Abstract][Full Text] [Related]
22. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.
Goffe B; Papp K; Gratton D; Krueger GG; Darif M; Lee S; Bozic C; Sweetser MT; Ticho B
Clin Ther; 2005 Dec; 27(12):1912-21. PubMed ID: 16507377
[TBL] [Abstract][Full Text] [Related]
23. An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis.
Krell J; Nelson C; Spencer L; Miller S
J Am Acad Dermatol; 2008 Apr; 58(4):609-16. PubMed ID: 18262681
[TBL] [Abstract][Full Text] [Related]
24. An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption.
Chu CY
J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):484-90. PubMed ID: 17373975
[TBL] [Abstract][Full Text] [Related]
25. An open-label study to evaluate the transition of patients with chronic plaque psoriasis from cyclosporine to alefacept.
Magliocco MA; Lozano AM; Van Saders C; Schuler KW; Gottlieb AB
J Drugs Dermatol; 2007 Apr; 6(4):424-7. PubMed ID: 17668540
[TBL] [Abstract][Full Text] [Related]
26. Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis.
Bovenschen HJ; Gerritsen WJ; van Rens DW; Seyger MM; de Jong EM; van de Kerkhof PC
Arch Dermatol Res; 2007 Feb; 298(9):457-63. PubMed ID: 17136563
[TBL] [Abstract][Full Text] [Related]
27. UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial.
Craig FF; Thomas KS; Mitchell EJ; Williams HC; Norrie J; Mason JM; Ormerod AD;
Trials; 2012 Apr; 13():51. PubMed ID: 22540770
[TBL] [Abstract][Full Text] [Related]
28. Open label trial of alefacept in palmoplantar pustular psoriasis.
Carr D; Tusa MG; Carroll CL; Pearce DJ; Camacho F; Kaur M; Cook C; Willard J; McCarty A; Fleischer AB; Liu CM; Goffe BS; Feldman SR
J Dermatolog Treat; 2008; 19(2):97-100. PubMed ID: 18512272
[TBL] [Abstract][Full Text] [Related]
29. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series.
Charles CA; Leon A; Banta MR; Kirsner RS
Int J Dermatol; 2007 Oct; 46(10):1095-9. PubMed ID: 17910724
[TBL] [Abstract][Full Text] [Related]
30. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study.
Mease PJ; Gladman DD; Keystone EC;
Arthritis Rheum; 2006 May; 54(5):1638-45. PubMed ID: 16646026
[TBL] [Abstract][Full Text] [Related]
31. Poor prognosis of arthritis-associated pyoderma gangrenosum.
Charles CA; Bialy TL; Falabella AF; Eaglstein WH; Kerdel FA; Kirsner RS
Arch Dermatol; 2004 Jul; 140(7):861-4. PubMed ID: 15262699
[TBL] [Abstract][Full Text] [Related]
32. Alefacept is safe and efficacious in the treatment of palmar plantar pustulosis.
Guenther LC
J Cutan Med Surg; 2007; 11(6):202-5. PubMed ID: 18042332
[TBL] [Abstract][Full Text] [Related]
33. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
Gottlieb AB; Kalb RE; Blauvelt A; Heffernan MP; Sofen HL; Ferris LK; Kerdel FA; Calabro S; Wang J; Kerkmann U; Chevrier M
J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792
[TBL] [Abstract][Full Text] [Related]
34. Intralesional injections of alefacept may predict systemic response to intramuscular alefacept: results from a pilot study.
Bhutani T; Kamangar F; Zitelli K; Chiang C; Gattu S; Nguyen T; Becker E; Koo J
J Dermatolog Treat; 2013 Oct; 24(5):348-50. PubMed ID: 22506829
[TBL] [Abstract][Full Text] [Related]
35. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
[TBL] [Abstract][Full Text] [Related]
36. Intravenous cyclophosphamide pulses in pyoderma gangrenosum: an open trial.
Reynoso-von Drateln C; Perla-Navarro AV; Gamez-Nava JI; Gonzalez-Lopez L; Galvan-Villegas F; Ramos-Remus C
J Rheumatol; 1997 Apr; 24(4):689-93. PubMed ID: 9101503
[TBL] [Abstract][Full Text] [Related]
37. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
Ellis CN; Krueger GG;
N Engl J Med; 2001 Jul; 345(4):248-55. PubMed ID: 11474662
[TBL] [Abstract][Full Text] [Related]
38. A bilateral comparison study of pimecrolimus cream 1% and a topical medical device cream in the treatment of patients with atopic dermatitis.
Emer JJ; Frankel A; Sohn A; Lebwohl M
J Drugs Dermatol; 2011 Jul; 10(7):735-43. PubMed ID: 21720655
[TBL] [Abstract][Full Text] [Related]
39. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
Vender R
J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
[TBL] [Abstract][Full Text] [Related]
40. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis.
Gribetz CH; Blum R; Brady C; Cohen S; Lebwohl M
J Am Acad Dermatol; 2005 Jul; 53(1):73-5. PubMed ID: 15965424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
